IVIM Health vs bmiMD: Compounded GLP-1 pricing and programs

IVIM Health vs bmiMD: quick verdict — IVIM Health emphasizes clinician-guided optimization and dual 4.9-star verification with a free-month code, while bmiMD emphasizes lower long-term monthly pricing for compounded tirzepatide and free subscription shipping. The choice depends on whether you prioritize IVIM’s satisfaction signals and proprietary GLP-1 ID protocol or bmiMD’s multi-month price tiers and shipping perks.

How they differ: pricing, programs, and meds

Both providers offer clinician-reviewed telehealth for compounded GLP-1 medications. Key differences supported by the sources include: IVIM lists semaglutide and tirzepatide pricing with a program fee and a promotional free month, and highlights a proprietary GLP-1 ID protocol and dual 4.9-star ratings. bmiMD lists tiered tirzepatide subscription pricing with lower long-term monthly equivalents and free subscription shipping plus 24/7 clinician access.

1. Pricing structure and commitments

IVIM Health: starts at $75 in listing and advertises $99 first month with $174/month ongoing and a $74.99/month program fee in some materials; new patients can use code GIFT75 for a free month membership and a no-obligation free consultation valued at $75. bmiMD: tirzepatide pricing is tiered with $179 month-to-month, $159 for a three-month plan, $149 for six months, and $139 for a 12-month plan; bmiMD notes the lowest price requires a 12-month commitment and advises confirming total prepaid charge and eligibility.

See bmiMD tirzepatide plans and shipping

2. Medication offerings and formulation notes

IVIM lists compounded semaglutide (GLP-1) at $75/mo and compounded tirzepatide at $133/mo alongside clinician-guided titration under GLP-1 ID. IVIM repeatedly states its compounded medications are not FDA-approved and have not undergone FDA review. bmiMD focuses on compounded tirzepatide with same price at every dose and the same regulatory note that compounded medications are not FDA-approved.

3. Program features and third-party validation

IVIM highlights a proprietary GLP-1 ID protocol that it says may accelerate weight loss by up to 40% compared to a published GLP-1 trial, and it emphasizes a 4.9-star rating on both Google and Trustpilot. These are presented as IVIM’s claims and published-study context, not head-to-head trial proof. bmiMD emphasizes 24/7 clinician access, online refills and delivery, and a “100% Risk Free” refund if not eligible for the program, per its captured copy.

Quick comparison table

Safety, claims, and what is supported

Both sources explicitly state compounded medications are not FDA-approved and have not been reviewed by FDA for safety, effectiveness, or quality. IVIM attributes a published-study context to its protocol outcomes and labels the 40% figure as a proprietary claim. bmiMD states medications are prepared in state-licensed pharmacies and highlights verification steps in captured copy. Neither source supplies head-to-head efficacy data between the two providers.

How to choose: IVIM Health vs bmiMD

If you prioritize independent satisfaction signals and a structured, clinician-guided optimization protocol with a promotional free month and a free consultation, IVIM Health is presented as the option that emphasizes those features. If you prioritize the lowest long-term monthly equivalent for compounded tirzepatide, clear multi-month billing tiers, and free subscription shipping, bmiMD is presented as the price-focused option. Remember both use compounded medications and note they are not FDA-approved.

Review bmiMD pricing and terms

Choose IVIM Health if you value dual 4.9-star third-party ratings, a no-obligation free consultation ($75 value), the GIFT75 free-month promotion, and a clinician-guided GLP-1 ID protocol. Choose bmiMD if you want lower long-term monthly rates for tirzepatide with free subscription shipping and tiered multi-month pricing; confirm prepaid totals and eligibility before enrolling.